The role of MDR-1 in refractory lymphoma

Leukemia and Lymphoma

Volumn 28, Issue 1-2, 1997, Pages 23-31

  Sandor, Victor ^a   Wilson, Wyndham ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Lymphoma; MDR 1; Multidrug resistance; P glycoprotein; Refractory lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PREDNISONE; VERAPAMIL; VINCRISTINE;

CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESISTANCE; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

EID: 0031427857     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709058327     Document Type: Review

References (44)

1. Fischer, R., Gaynor, E., Dahlberg, S., et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 328, 1002-1006.
2. Juliano, R. and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-162.
3. Roninson, I. B., Abelson, H. T., Hausman, D. E., et al. (1984). Amplification of specific DNA sequences correlates with multidrug resistance in Chinese hamser cells. Nature, 309, 626-631.
4. Ling, V. (1992). P-glycoprotein and resistance to anticancer drugs. Cancer, 69, 2603-2609.
5. Divita, V. T., et al. (1993). Cancer Principles and Practice of Oncology, 4th ed. pp. 1906-1907. (Lippincott, Philadelphia.)
6. Tsuruo, T., Iida H., Tsukagoshi, S., et al. (1981). Overcoming of vincristine resistance in P-388 leukemia in vivo through enhanced cytoloxicity to vincristine and vinblastine by verapamil Cancer Res, 41, 1967-1972.
7. Slater, L. M., Sweet, P., Stupecky, M., et al. (1986). Cyclosporin A reverses vincristine resistance in acute lymphatic leukemia in vitro. J Clin Invest, 77, 1405-1408.
8. Ford, J. M. and Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev, 42, 155-199.
9. Twentyman, P. and Bleehen, N. (1991). Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer, 27, 1639-1642.
10. Hauberman, K., Benz, B., Gekler, V., et al. (1991). Effect of verapamil enanteomeres and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma lines. Eur J Clin Pharmacol, 40, 53-59.
11. Moscow, J. A., Fairchild, C. R., Madden, M. J., et al. (1989). Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res, 49, 1422-1428.
12. Goldstein, L., Galski, H., Fojo, A., et al. (1989). Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst, 81, 116-124.
13. Schlaifer, D., Laurent, G., Chittal, S., et al. (1990). Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumor and stromal cells of human cancers. Br J Cancer, 62, 177-182.
14. Miller, T. P., Grogan, T. M., Dalton, W. S., et al. (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil. J Clin Onc, 9, 17-24.
15. Pileri, S., Sabattini, E., Falini, B., et al. (1991). Immunohistochemicaldetection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology, 19, 131-140.
16. Poje, E., Bierman, P., Daley, D., et al. (1991). Expression of P-glycoprolein in B-cell non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res, 32, 366. [abstr.]
17. Niehans, G. A., Jaszcz, W., Brunetto, V., et al. (1992). Immunohistochemical detection of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res, 52, 3768-3775.
18. Rodriguez, C., Commes, T., Robert, J., et al. (1993). Expression of P-glycoprotein and anionic glutathion-S transferase genes in non-Hodgkin's lymphoma. Leuk Res, 17, 149-156.
19. Cheng, A. L., Su, I. J., Chen, Y. C., et al. (1993). Expression of P-glycoprotein and glutathione transferase in recurrent lymphomas: The possible role of Epstein Barr virus, immunophenotypes, and other predisposing factors. J Clin Onc, 11, 109-115.
20. Gascoyne, R., Tolcher, A., Van Iderstine, E., et al. (1993). The prognostic relevance of p-glycoprotein expression in malignant lymphomas. Proceedings of the General Motors Cancer Research Foundation International Symposium (Toronto, 1993), [absr.#A7]
21. Kang, Y., Zhan, Z., Regis, J., et al. (1995). Expression of mdr-1 in refractory lymphoma: Quantitation by polymerase chain reaction and validation of the assay. Blood, 86, 1515-1524.
22. Kartner, N., Evernden, P. D., Bradley, G., et al. (1985). Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature, 316, 820-823.
23. Herzog, C. E. and Bates, S. E. (1994). Molecular diagnosis of multidrug resistance. In: Anticancer Drug Resistance: Advances in Molecular and Clinical Research, pp. 129-147, Goldstein L.J. and Ozols R. F. (eds.) (Kluwer Academic Publishers.)
24. Beck, W. T., Grogan, T. M., Willman, C. L., et al. (1996). Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Concensus recommendations. Cancer Res, 56, 3010-3020.
25. Hamada, H. and Tsuruo, T. (1986). Functional role for the 170- to 180- kDa glycoprotein specific to drug resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci, 83, 7785-7789.
26. Schinkel, A. H., Arceci, R. J., Smith, J. J., et al. (1993). Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer, 55, 478-484.
27. Gros, P., Raymond, M., Bell, J., et al. (1988). Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol, 8, 2770-2778.
28. Buschman, E. and Gros, P. (1991). Functional analysis of chimeric genes obtained by exchanging homologous domains of mouse mdr-1 and mdr-2 genes. Mol Cell Biol, 11, 595-603.
29. Rao, V. V., Anthony, D. C. and Piwnica-Worms, D. (1994). MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res, 54, 1536-1541.
30. Chan, H. S., Bradley, G., Thorner, P., et al. (1988). A sensitive method for immunohistochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines. Lab Invest, 59, 870-875.
31. Chao, C. K. (1995). Lack of elevated drug efflux in adriamycin-resistant immunoblastic B-lymphoma cells with mdr-1 overexpression. FEBS Letters, 373, 285-290.
32. Leith, C. P., Chen, I. M., Kopecky, K. J., et al. (1995). Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MRD+/efflux- cases. Blood, 86, 2329-2342.
33. Seymore, L., Daviidge-Pitts, M., Lewis, D., et al. (1993). P-glycoprotein: low constitutional expression does not correlate with treatment failure in follicular lymphomas. Int J Oncol, 2, 1067-1070.
34. Twentyman, P. R. and Versantvoort, C. H. (1996). Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer, 32A, 1002-1009.
35. Lee, J. J., Hughes, C. S., Fine, R. L., et al. (1996). P-glycoprotein expression in canine lymphoma a relevant, intermediate model of multidrug resistance. Cancer, 77, 1892-1898.
36. Weinstein, R. S., Jakate, S. M., Dominguez, J. M., et al. (1991). Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res, 51, 2720-2726.
37. Tobe, S. W., Noble-Topham, S. E., Andrulis, I. L., Hartwick, W. J., Skorecki, K. L. and Earner, E. (1995). Expression of the multiple drug resistance gene in human renal cell carcinoma depends on tumor histology, grade, and stage. Clin Cancer Res, 1, 1611-1615.
38. Goldstein, L. J. (1995). Clinical reversal of drug resistance. Curr Probl Cancer, 19, 65-124.
39. Wilson, W. H., Bates, S. E., Fojo, A., et al. (1995). Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol, 13, 1995-2004.
40. Yahada, A. M., Adler, K. M., Fisher, G. A., et al. (1992). Phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol, 10, 1624-1634.
41. Cobb, P., Burris, H., Weiss, G., et al. (1995). Phase I trial of PSC 833 and doxorubicin, Vincristine, cyclophosphamide, and prednisone (DVCP) in patients with refractory non-Hodgkin's lymphoma Proc. Annu Meet Am Soc Clin Oncol, 14, A 1578 [abstr.]
42. Sarris, A. H., Younes, A., McLaughlin, P., et al. (1996). Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol, 14, 233-239.
43. Wilson, W. H., Chabner, B. A., Bryant, G., et al. (1995). Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncl, 13, 381-386.
44. Futscher, B. W., Foley, N. E., Gleason-Guzman, M. C., et al. (1996). Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer, 66, 520-525.